# Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

> **NCT03304080** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 44 (actual)

## Conditions studied

- Breast Neoplasms
- Breast Diseases

## Interventions

- **DRUG:** Anastrozole
- **DRUG:** Palbociclib
- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab

## Key facts

- **NCT ID:** NCT03304080
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-12-20
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2025-07-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03304080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03304080, "Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03304080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*